As Johnson & Johnson kick-starts phase 3 COVID-19 test, early data show up its promise

Johnson & Johnson has posted an early peek at its phase 1/2 trial data for its pandemic vaccine hopeful that last week started late-stage tests.

The data (PDF), which are in preprint (so caveats abound), showed its vaccine, Ad26.COV2.S (now also known as JNJ-78436735), producing an immune response at one dose, giving a boost to its late-stage single shot focus.